Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 12, 2005, Pages 651-653

  Chen, Shu Huey ^a,b   Liang, Der Cherng ^a   Lin, Hung Ching ^a   Cheng, Shu Yun ^a   Chen, Lee Jen ^a   Liu, Hsi Che ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NONE   (Taiwan)

Author keywords

Deferoxamine; Ototoxicity; Thalassemia; Visual toxicity

Indexed keywords

CHELATING AGENT; DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; FUNCTION TEST; HEARING ACUITY; HEARING IMPAIRMENT; HEMOCHROMATOSIS; HUMAN; MALE; MEDICAL ASSESSMENT; OPHTHALMOSCOPY; OTOTOXICITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCHOOL CHILD; THALASSEMIA; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT;

ACOUSTIC IMPEDANCE TESTS; ADOLESCENT; ADULT; ANEMIA, HEMOLYTIC, CONGENITAL; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; DEFEROXAMINE; FEMALE; FERRITINS; HEARING LOSS, SENSORINEURAL; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; IRON CHELATING AGENTS; MALE; OPHTHALMOSCOPY; VISION DISORDERS; VISUAL ACUITY;

EID: 29144466570     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/01.mph.0000194019.95096.b6     Document Type: Article

References (23)

1. Sephton-Smith R. Iron excretion in thalassemia major after administration of chelating agents. Br Med J. 1962;2:1577-1580.
2. Propper RD, Cooper B, Rufo RR, et al. Continuous subcutaneous administration of desferrioxamine in patients with iron overload. N Engl J Med. 1977;297:418-423.
3. Cohen A, Martin M, Mizanin J, et al. Vision and hearing during desferrioxamine therapy. J Pediatr. 1990;117:326-330.
4. Mehta AM, Engstrom RE, Kreiger AE. Deferoxamine-associated retinopathy after subcutaneous injection. Am J Ophthalmol. 1994;118:260-261.
5. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions. N Engl J Med. 1986;314:869-873.
6. Orton RB, de Veber LL, Sulh HM. Ocular and auditory toxicity of long-term, high dose subcutaneous deferoxamine therapy. Can J Ophthalmol. 1985;20:153-156.
7. Porter JB, Jaswon MS, Huehns ER, et al. Desferrioxamine ototoxicity: evaluation of risk factors in thalassemic patients and guidelines for safe dosage. Br J Haematol. 1989;73:403-409.
8. De Virgiliis S, Argiolu F, Sanna G, et al. Auditory involvement in thalassemia major. Acta Haematol. 1979;61:209-215.
9. Marciani MG, Stefani N, Stefanini F, et al. Visual function during long-term desferrioxamine treatment. Lancet. 1993;341:491.
10. Masala W, Meloni F, Gallisai D. Can deferoxamine be considered an ototoxic drug? Scand Audiol Suppl. 1988;30:237-238.
11. Styles LA, Vichinsky EP. Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine. J Pediatr Hematol Oncol. 1996;18:42-45.
12. Ambrosetti U, Donde E, Piatti G, et al. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment. Pharmacol Res. 2000;42:485-487.
13. Haimovici R, D'Amico D, Gragoudas ES, et al. The expanded clinical spectrum of deferrioxamine. Ophthalmol. 2002;109:164-171.
14. Albera R, Pia F, Morra B. Hearing loss and desferrioxamine in homozygous beta thalassemia. Audiology. 1988;27:207-214.
15. Wonke B, Hoffbrand AV, Aldouri M, et al. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA. Arch Dis Child. 1989;64:77-82.
16. Argiolu F, Diana G, Avignone A, et al. Hearing impairment during deferoxamine therapy for thalassemia major. J Pediatr. 1991;118:826-827.
17. Kontzoglou G, Koussi A, Tsatra J, et al. Sensorineural hearing loss in children with thalassemia major in Northern Greece. Int J Otorhinolaryngol. 1996;35:223-230.
18. Karimi M, Asadi-Pooya AA, Khademi B, et al. Evaluation of incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine. Acta Haematol. 2002;108:79-83.
19. Chiodo AA, Alberti PW, Sher GD, et al. Desferrioxamine ototoxicity in an adult transfusion-dependent population. J Otolaryngol. 1997;26:116-122.
20. De Virgiliis S, Congia M, Turco MP, et al. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassemia. Arch Dis Child. 1988;63:250-255.
21. Pall H, Blake DR, Winyard P, et al. Ocular toxicity of desferrioxamine. An example of copper promoted auto-oxidative damage? Br J Ophthalmol. 1989;73:42-47.
22. Davies SC, Marcus RE, Hungerford JL, et al. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 1983;2:181-184.
23. Davies MJ, Donkor R, Dunster CA, et al. Desferrioxamine (Desferal) and superoxide free radicals. Biochem J. 1987;246:725-729.